Physician profile
Jairo Gomez
NPI 1417055104
$19,698.60
in general payments reported to CMS, 2019-2025
15 companies · $3,151 in 2025
The $3,151 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,679 · 2020: $1,612 · 2021: $2,354 · 2022: $3,122 · 2023: $2,762 · 2024: $3,018 · 2025: $3,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,915 · Education: $16.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,914.90 |
| Education | $16.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,881.04 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $3,086.14 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $2,048.37 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,679.85 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $1,516.72 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Allergan, INC. | $1,095.45 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $821.75 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $809.67 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $531.81 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $404.32 | 2024-2025 | Cobenfy |
| Indivior INC. | $266.54 | 2019-2022 | |
| Eisai INC. | $182.00 | 2020-2021 | |
| Lundbeck LLC | $166.83 | 2019-2022 | |
| Janssen Biotech, INC. | $122.71 | 2025 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $85.40 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairo Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.